SCHEMBL3076935

SCHEMBL3076935

O=C(O)n1cc(-c2ccc(Br)cc2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.39
MCL1 Q07820 3/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 1/20 0.39
ELANE P08246 4/20 0.38
PLAU P00749 3/20 0.38
F2 P00734 1/20 0.38
KLKB1 P03952 1/20 0.38
ALAD P13716 1/20 0.38
HAO1 Q9UJM8 1/20 0.38
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTPN1 P18031 1/20 0.37
ROCK2 O75116 1/20 0.36
KDM4E B2RXH2 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28712249 0.82 F2 (0.45) MCL1ALDH1A1ELANEPLAUF2
SCHEMBL17394741 0.82 ALDH1A1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2ROCK2
SCHEMBL28710155 0.82 BCL2L1 (0.46) ALDH1A1ELANEPLAUF2KLKB1
SCHEMBL28700571 0.82 MAP4K4 (0.50) KCNH2ALDH1A1ELANEPLAUF2
SCHEMBL28705426 0.79 MMP3 (0.44) MMP2MMP3
SCHEMBL28713751 0.78 MAPKAPK2 (0.53) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL22353120 0.77 F2 (0.49) ALDH1A1MAPK1ELANEPLAUF2
SCHEMBL3087005 0.77 ROCK2 (0.60) KCNH2ELANEPLAUF2KLKB1
SCHEMBL28710153 0.76 SMN1; SMN2 (0.44) MCL1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL21275444 0.75 MKNK1 (0.50) ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2010-09-09 US disclosed
EP-2176256-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES AstraZeneca AB (SE) 2010-04-21 EP disclosed
WO-2009007751-A2 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES ASTRAZENECA AB (SE) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227858-A1 TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES MTOR, PIK3CA, PIK3CD KCNH2 4617/4885MCL1 1009/4885ALDH1A1 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.